Consensus Acelyrin, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 02:38:39 2024-05-10 pm EDT			5-day change	1st Jan Change
4.55 ^USD	-6.76%		+5.86%	-38.27%

May. 09	Acelyrin, Inc. Announces Ron Oyston to Step Down as Chief People Officer, Effective August 15, 2024	CI
May. 09	Acelyrin, Inc. Announces CEO Changes	CI

1f95146c6.iFl_hxoEJcaM-PTAr45-jBoev73jLA6GQjeU-n-Rj9I.8mg-xn89S7z_rqPxnecWvkhW-_qJGUXtDWKmyRP0upXtajmzX0dV8PutuQ~149ebad189e575212898507877414b65

Wells Fargo Raises ACELYRIN's Price Target to $13 From $11, Keeps Equalweight Rating	Mar. 21	MT
Wells Fargo Starts Coverage on ACELYRIN with Equalweight Rating, $11 Price Target	Dec. 13	MT
Citigroup Initiates ACELYRIN at Neutral Rating With $8 Price Target	Dec. 08	MT
Morgan Stanley Adjusts Price Target on ACELYRIN to $13 From $19, Maintains Equal-Weight Rating	Nov. 28	MT
Jefferies Adjusts ACELYRIN Price Target to $12 From $15, Maintains Buy Rating	Nov. 28	MT
Morgan Stanley Downgrades ACELYRIN to Equalweight From Overweight, Cuts Price Target to $19 From $39	23-09-13	MT
Morgan Stanley Adjusts Price Target on Acelyrin to $39 From $29, Maintains Overweight Rating	23-09-05	MT
HC Wainwright Starts Acelyrin at Buy, $44 Price Target	23-09-05	MT
Morgan Stanley Initiates Coverage on Acelyrin With Overweight Rating, $29 Price Target	23-05-30	MT
Jefferies Starts Acelyrin at Buy With $31 Price Target	23-05-30	MT
Piper Sandler Initiates Acelyrin at Overweight With $68 Price Target	23-05-30	MT
TD Cowen Starts Acelyrin at Outperform	23-05-30	MT

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.88 USD

Average target price

22.5 USD

Spread / Average Target

+361.07%

High Price Target

68 USD

Spread / Highest target

+1,293.44%

Low Price Target

8 USD

Spread / Lowest Target

+63.93%